Consolidated Statements of Comprehensive Loss (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:
Clinical treatment programs	$ 36	$ 39	$ 114	$ 160
Total revenues	36	39	114	160
Costs and expenses:
Production/cost of goods sold	252	988	1,078	1,476
Research and development	2,173	2,357	6,827	5,758
General and administrative	2,070	1,659	5,964	5,271
Total costs and expenses	4,495	5,004	13,869	12,505
Operating loss	(4,459)	(4,965)	(13,755)	(12,345)
Interest expense	(4)	(7)	(14)	(19)
Interest and other income	89	353	624	873
Other than temporary impairment loss on marketable securities	(800)	0	(800)	0
Funds received from sale of income tax net operating losses	0	0	686	1,328
Redeemable warrants valuation adjustment	38	(1,968)	229	(1,732)
Net loss	(5,136)	(6,587)	(13,030)	(11,895)
Other Comprehensive Income (Loss):
Unrealized gain (loss) on marketable securities	867	306	(93)	890
Realized gain (loss) on marketable securities	131	(168)	44	(205)
Less: Premium amortization	(1)	24	1	132
Net comprehensive loss	$ (4,139)	$ (6,425)	$ (13,078)	$ (11,078)
Basic and diluted loss per share (usd per share)	$ (0.03)	$ (0.05)	$ (0.08)	$ (0.09)
Weighted average shares outstanding, basic and diluted (shares)	167,389,685	137,012,240	167,135,111	136,260,727